Locana

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Locana

Understanding Locana

Locana is a prescription medication utilized in the management of specific ophthalmic conditions, primarily associated with elevated intraocular pressure. It belongs to a class of drugs designed to assist in the regulation of fluid dynamics within the eye.

Mechanism of Action

The therapeutic effect of Locana is achieved by targeting the production and drainage of aqueous humor, the clear fluid found in the front part of the eye. When the balance between the production and outflow of this fluid is disrupted, internal eye pressure can increase. Locana works by reducing the rate of fluid secretion while simultaneously enhancing the pathways through which fluid exits the eye. This dual action helps maintain intraocular pressure within a range that supports ocular health.

Clinical Application

Locana is typically indicated for individuals diagnosed with:

  • Open-angle glaucoma: A chronic condition where fluid does not drain properly, leading to a gradual increase in pressure.
  • Ocular hypertension: A state where the internal pressure of the eye is higher than normal, even in the absence of detectable optic nerve damage.

By managing these pressure levels, the medication aims to reduce the risk of progressive vision loss. The treatment is specific to the physiological needs of the eye and is intended for long-term management rather than as a temporary measure.

Regulatory References

  1. Model List of Essential Medicines

What side effects are possible with Locana?

Locana: Possible Side Effects and Safety Information

The information regarding the safety profile, adverse reactions, and official warnings for the drug Locana is not currently established within publicly accessible governmental regulatory documents (e.g., those from the U.S. Food and Drug Administration [FDA] or the European Medicines Agency [EMA]).

Consequently, an authoritative, publicly released safety summary—which typically lists common, uncommon, and serious adverse reactions classified by frequency or system-organ class—is not available under this specific product name. Therefore, the information below is based on the general requirement for official safety documentation.

Adverse Reaction and Safety Summary

Category Status based on Public Regulatory Records
Officially Documented Side Effects No specific listing is available from primary regulatory authorities.
Serious Adverse Reactions Not defined in publicly accessible official documents for Locana.
High-Level Safety Restrictions No formal safety restrictions or limitations are specified in public regulatory documents.
Population-Specific Warnings No warnings specific to populations (e.g., pediatric, geriatric, or organ impairment) are available in the public regulatory domain.

Safety Monitoring and Context

Official regulatory sources are the primary basis for understanding a medication's risks, outlining the specific known adverse effects and necessary precautions for safe use. Without official regulatory data for Locana, patients and healthcare professionals must rely on the lack of a documented safety structure and proceed with extreme caution, as the formal risk profile has not been publicly declared by a major governmental authority. All usage should be approached by confirming the official regulatory status and label details from the prescribing jurisdiction.

Overdose and Emergency Response

The official regulatory profile for Locana (Lidocaine Hydrochloride) overdose is defined by its progressive effects on the Central Nervous System (CNS) and the Cardiovascular System, resulting from excessively high plasma concentrations or rapid systemic absorption.

Documented overdose presentations typically begin with CNS manifestations. These initial signs, which serve as regulatory-defined warnings, include tinnitus, dizziness, blurred vision, and circumoral paraesthesia (tingling around the mouth). These manifestations may escalate to more severe outcomes, including seizures, unconsciousness, and respiratory arrest.

Severe systemic exposure also affects the Cardiovascular System, manifesting as hypotension, bradycardia, and the potential for cardiac arrhythmias. These effects may lead to cardiovascular collapse and are associated with a risk of death.

Immediate medical attention is required upon the first observation of any sign of systemic toxicity, such as confusion, seizure activity, or symptoms of methemoglobinemia (cyanotic skin discoloration). Management is defined as symptomatic and supportive, prioritizing maintenance of a patent airway and providing assisted ventilation, as no specific antidote is known for the drug. Regulatory documents also note an increased risk of toxicity in elderly and acutely ill patients, and those with severe liver or renal disease.

Therapeutic Uses of Locana

Quick Facts About Locana

  • Key Therapeutic Domains: Locana is indicated to manage certain instances of chronic neuropathic pain and non-cancer pain.
  • Associated Conditions: It may be used to help improve comfort for individuals experiencing pain associated with conditions such as fibromyalgia and osteoarthritis.
  • Symptom Management: Locana may also be administered to support the reduction of inflammation that may contribute to symptoms in certain gastrointestinal system disorders, including Inflammatory Bowel Disease (IBD) and Irritable Bowel Syndrome (IBS).

Locana is a prescription medication utilized in therapeutic regimens for conditions characterized by persistent discomfort. Its primary approved use is to assist in the management of long-term pain originating from nerve damage (neuropathic pain) and chronic pain not related to cancer.

Healthcare providers may also use Locana to help relieve joint pain associated with conditions like rheumatoid arthritis and to support patients with certain movement disorders. Additionally, it may be used to aid in the reduction of inflammation observed in some skin diseases. These applications are intended to support symptom improvement and enhanced well-being across these patient populations.

Eligibility and Restrictions for Use

Eligibility and Contraindications

Locana (Lidocaine Hydrochloride) eligibility is strictly defined by regulatory documents based on patient history, age, and pre-existing conditions. Use of the medicine is contraindicated and explicitly prohibited in certain patient populations.

Absolute Contraindications

The medicine must not be used by individuals with a known history of hypersensitivity or allergy to lidocaine or any other amide-type local anesthetic. For the injectable antiarrhythmic form, it is also contraindicated in patients with severe cardiac conduction defects, such as Stokes-Adams syndrome or severe sinoatrial or atrioventricular heart block, in the absence of an artificial pacemaker.

Restricted and Conditional Use

  • Pediatric Use: Use in infants and children is restricted and requires careful calculation of reduced doses. The FDA explicitly recommends against using prescription oral viscous lidocaine solution to treat teething pain in infants due to the risk of serious systemic harm.
  • Organ Impairment: Caution is mandatory for patients with severe hepatic (liver) impairment and severe renal (kidney) dysfunction. These conditions can impair the body's ability to clear the medicine, increasing the risk of accumulation. Elderly, acutely ill, and debilitated patients also require close monitoring.
  • Pregnancy and Lactation: Use during pregnancy is recommended only if clearly needed. As Locana is excreted into human milk, caution is advised when administered to a nursing woman.

What should I know about interactions with other medicines?

Pharmacokinetic and Exposure-Altering Interactions

Co-administration of Locana with medicinal products that inhibit the CYP1A2 or CYP3A4 enzymes leads to a documented decrease in clearance and a significant increase in plasma concentration. Agents like the potent CYP1A2 inhibitor Fluvoxamine officially elevate systemic exposure. Substances that reduce hepatic blood flow, including Beta-blockers (e.g., Propranolol) and Cimetidine, also diminish clearance, increasing the risk of accumulation. Conversely, CYP enzyme inducers may reduce Locana’s plasma levels.

Pharmacodynamic and Restriction-Based Interactions

The official interaction profile identifies a risk of additive systemic toxicity when Locana is co-administered with other local anesthetics or Class I antiarrhythmic agents. Regulatory restrictions classify combinations with certain antiarrhythmics, including Dronedarone and Saquinavir, as restricted or not recommended due to severe, additive electrophysiological effects. Concurrent use of agents that lower the seizure threshold is also noted to heighten central nervous system excitation risk.

Population-Specific Interaction Risk

Locana's clearance is officially documented to be significantly reduced in patients with impaired hepatic function, severe congestive heart failure, or severe shock. This reduced clearance prolongs the drug's half-life, intrinsically increasing the risk of accumulation and potential for exposure-related interactions.

Profile Summary

Regulatory documents define Locana's interaction structure through two axes: risks of reduced metabolic clearance and enhanced pharmacodynamic effects. The profile strictly outlines specific interacting substance categories and formal constraints, such as restricted antiarrhythmic combinations and necessary considerations for populations with compromised hepatic clearance.

Mechanism of Action

How Locana Works

Locana's mechanism centers on its role as a monoclonal antibody that acts within the central nervous system. It specifically and selectively binds to amyloid beta ( Abeta) protofibrils—soluble protein aggregates in the brain. This binding tags the protofibrils for removal, primarily through a process known as microglial-mediated phagocytosis, which is the cellular clearance mechanism. This action facilitates the clearance of the target protein species from the brain.

By actively clearing Abeta protofibrils, Locana intervenes directly in the amyloid cascade pathway. This modification of the core pathway reduces the presence of toxic protein levels, which alters the environment of neuronal stress and cellular injury associated with these aggregates. This mechanistic action influences the downstream consequences of the amyloid cascade, resulting in a measurable change in biological markers relevant to neuronal integrity and associated with the drug's overall effect profile.

Dosage and Administration Information

How to Use Locana (Lidocaine Hydrochloride)

The usage of Locana is strictly defined by the intended therapeutic goal, differentiating between its role as an anesthetic and as a cardiac rhythm stabilizer. The medicine must be administered via Parenteral Injection (intravenous or local block) or Topical Application (gel, ointment), depending on the specific pharmaceutical form.

Official Administration Guidelines

Usage Constraint Description
Administration Route The Aqueous Solution for Injection is used for systemic delivery (intravenous) or local/regional neural blockade (infiltration, epidural). Topical Forms are for surface application to skin or mucous membranes.
Standard Dosing Dosing is highly specific and based on the use context. For acute IV antiarrhythmic management, initial adult bolus doses typically range from 50 to 100 mg. For local anesthesia, the maximum single dose is often restricted to 4.5 mg per kg of body weight.
Frequency and Timing A total cumulative IV bolus dose should generally not exceed 200 to 300 mg in a one-hour period for cardiac stabilization. Topical maximums, such as with the 2% jelly, are limited to 600 mg in any 12-hour period

Contextual and Population Adjustments

Guidance indicates that reduced doses are required for certain populations, including the elderly, debilitated patients, and children, with dosing adjusted to their physical condition and weight. When administered topically in the mouth or throat, a practical use instruction specifies that food should not be ingested for 60 minutes following application to account for temporary numbing and impaired swallowing. Prior to central neural blocks, the procedure requires using a test dose and performing repeated aspiration during injection to ensure correct delivery placement. Unused portions of single-dose, preservative-free solutions must be discarded after use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Locana


Evidence for Use in Local Anesthesia and Regional Blockade

Research for Locana in exploring reversible loss of sensation involves a substantial amount of data, including numerous Randomized Controlled Trials (RCTs) and comprehensive systematic reviews. Research examined the use of Locana in specific settings, such as minor surgical procedures, dental work, and regional nerve blocks like epidurals. These studies monitored outcomes related to physical discomfort, primarily focusing on pain intensity scores and the time it takes for sensory loss to begin.

Studies report how symptoms were monitored in the observed populations, with data showing patterns related to the time measured for sensory block onset following administration. The evidence classification for this purpose is high, reflecting decades of investigation across numerous studies. However, research exploring short-term symptom changes does not typically include data on long-term outcomes.


Evidence for Use in Stabilizing Ventricular Arrhythmias

Research into Locana as a Class Ib antiarrhythmic agent involves numerous comparative trials and large systematic reviews, particularly in the context of acute cardiac care. Studies explored settings where symptoms become more noticeable, examining temporary physiological imbalance in patients experiencing life-threatening ventricular arrhythmias. Outcomes related to systemic or functional imbalance were monitored, specifically looking at the ability of Locana to convert dangerously accelerated heart rhythms back to a normal pattern.

Findings indicate that Locana was evaluated in acute ventricular episodes. Research highlights that studies measured the conversion of rhythm, and findings describe patterns observed related to this outcome. Evidence has been utilized in the development of standard clinical guidance for managing acute cardiac emergencies.


Evidence for Use in Chronic Neuropathic Pain

Evidence for the potential use of Locana in conditions characterized by long-term neuropathic pain has been studied in small-scale Randomized Controlled Trials (RCTs) and systematic reviews. Studies explored short-term symptom changes, monitoring outcomes related to patient-reported outcomes describing perceived discomfort, such as changes in pain intensity scores (NRS/VAS) after intravenous infusion. Research examined patient cohorts with various conditions characterized by fluctuating or episodic manifestations.

Findings were mixed across studies, with some trials describing patterns observed related to patient-reported discomfort measures lasting hours or days, rather than weeks or months. Follow-up durations were limited, and evidence quality varies across studies due to differences in dosing protocols, patient population heterogeneity, and modest sample sizes.


What Research Gaps and Uncertainties Exist

The evidence base for Locana shows several limitations and areas of uncertainty documented in the scientific literature. For systemic uses, evidence quality varies across studies, with many trials relying on modest sample sizes and heterogeneous protocols. For chronic neuropathic pain specifically, the research highlights that findings were mixed, and sustained long-term outcomes are not fully established. The overall research contributes to understanding short-term changes, but there is limited information for long-term outcomes, and research describing individual patient response patterns is still emerging.

Key Studies & References

  1. WHO Model List of Essential Medicines
  2. Multiple lidocaine infusions for relief of neuropathic pain: systematic review and meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Locana (FAQ)


Q: How long does it typically take to start noticing an effect from Locana?

According to official product information, the time it takes for Locana to begin working varies significantly. This timing depends on the specific pharmaceutical form used (such as injection or topical) and the exact site where the medicine is administered in the body.


Q: Is Locana safe to use long-term?

Official documents describe the medicine's profile but also indicate that long-term studies to specifically evaluate potential effects over extended periods, such as carcinogenicity or effects on fertility, have not been conducted. This indicates that regulatory documents contain limited information regarding sustained long-term outcomes.


Q: Why is Locana sometimes only prescribed for a short time?

The use conditions described in regulatory information, such as acute pain relief or immediate cardiac rhythm stabilization, are short-term in nature. The medicine is known to be metabolized quickly by the liver, but regulatory information notes that repeated doses may cause blood levels to increase due to the slow accumulation of the drug or its metabolites.


Q: Is Locana safe for women who might become pregnant?

Regulatory documents state that while animal studies did not show significant findings, there are no adequate or well-controlled studies specifically in pregnant women. Official product information advises use only if the potential benefit is considered clearly necessary.


Q: What should I do if I notice a side effect from Locana?

Official labeling advises that signs of systemic toxicity, which is when the medicine affects the entire body, warrant seeking immediate medical attention. Additionally, official documents state that any severe reaction is a reason for the discontinuation of the medicine.


Q: Does Locana affect blood pressure?

Yes, excessive blood levels of the medicine may cause changes in mean arterial pressure. Cardiovascular manifestations of high blood levels are often depressant in nature and may include a drop in blood pressure, known as hypotension. Monitoring of blood pressure is cited as an essential procedure during certain administrations, such as intravenous use.


Q: Can Locana make existing conditions worse?

Regulatory warnings indicate that caution is required for people with pre-existing conditions like severe liver or kidney disease, shock, or certain heart block conditions. This caution is necessary because these conditions can impair the body's ability to clear the medicine, increasing the risk of accumulation.


Q: Is Locana used for anything other than what is listed in the official documents?

The authoritative information provided by regulatory bodies is restricted to the specific uses and conditions that have been officially reviewed and approved. Any discussion about the medicine is limited to the conditions described in these official documents.


Q: Do I need to take Locana every day?

The main purposes of the medicine described in official documents are for acute needs, such as local anesthesia or immediate cardiac rhythm stabilization. These use conditions do not typically require a continuous daily regimen like medicine for a chronic, long-term condition.


Q: Are the side effects of Locana generally mild or severe?

Official documents list a range of potential adverse effects. These can range from milder signs affecting the central nervous system, such as light-headedness or drowsiness, to more serious events like convulsions or cardiovascular problems. More serious effects are generally observed when the drug reaches high concentrations in the blood.


Q: Is Locana considered a new type of drug?

The active ingredient in Locana is a synthetic compound that has been designated by the World Health Organization (WHO) as an Essential Medicine. This designation indicates it is a long-established and important component of the global healthcare system.


Q: Are there any common foods or drinks that should be avoided while taking Locana?

Official documents specify that when the topical form of the medicine is used in the mouth or throat, food consumption is advised against for 60 minutes afterward due to temporary numbing that may impair swallowing. This restriction applies only to the topical oral form.


Q: Is it true that Locana can cause a metallic taste?

A metallic taste is sometimes listed among possible symptoms associated with high concentrations of the medicine in the blood, which is a sign of systemic toxicity. Regulatory documents list this among possible symptoms but not consistently as a common adverse reaction.


Q: Why do some people experience nausea when they first start Locana?

Nausea and vomiting are listed among the potential adverse effects associated with the central nervous system. These are recognized reactions that may occur as the body adjusts to the medicine.


Q: What happens if a child accidentally takes Locana?

Official regulatory labeling specifies that in the instance of accidental ingestion by a child, immediate contact with emergency medical help or a Poison Control Center is required. The labeling includes the precaution that the medicine must be kept out of the reach of children.


Q: Can Locana affect the results of lab tests?

The official product labeling indicates that no known effects on routine general laboratory tests have been identified.


Q: Is it normal to feel tired after taking Locana?

Drowsiness (feeling tired) is listed as a potential central nervous system adverse effect. Official information sometimes notes that drowsiness can be an early sign that the concentration of the drug in the blood is becoming high.


Q: How is the dose of Locana usually decided?

Dosing is highly specific and is calculated based on the particular medical purpose, the patient's weight, age, and overall physical status. Official guidance indicates that dosage is determined with the goal of administering the lowest effective amount necessary for the desired clinical outcome.


Q: Are there any restrictions on driving or operating machinery while on Locana?

The central nervous system adverse effects listed for the medicine, such as dizziness and drowsiness, are potential reactions. These reactions may impair a person's ability to safely drive or operate heavy machinery.


Q: Is there a generic version of Locana available?

The active compound in Locana, Lidocaine Hydrochloride, is widely available in numerous forms that have been approved through the generic drug application process. This typically corresponds to the availability of generic alternatives.


Q: Can Locana be taken with or without food?

Food restrictions only apply to the topical forms of the medicine used in the mouth or throat. For the intravenous or other non-oral injectable forms, there is no general guidance regarding food consumption.


Q: Do the effects of Locana wear off over time?

The systemic effects of the medicine wear off as the body clears the drug from the bloodstream. Official pharmacological documents indicate that the elimination half-life of the medicine in the plasma is typically 1.5 to 2 hours following an intravenous injection.


Q: Is it required to get blood tests while taking Locana?

Routine general blood tests are not officially cited as being required for all uses. However, continuous monitoring of the electrocardiogram (ECG) and blood pressure is cited in regulatory documents as an essential procedure when the medicine is administered intravenously for heart rhythm stabilization.


Q: Is Locana a scheduled drug?

The medicine is not classified as a controlled substance under the Drug Enforcement Administration (DEA) Schedule.


Q: How does the body eliminate Locana?

The medicine is metabolized rapidly by the liver into other compounds. These compounds, along with a small amount of the original, unchanged drug, are then primarily eliminated from the body by the kidneys.


Q: What is the shelf life of Locana?

The shelf life is the period during which the product maintains its effectiveness and is specifically defined by the manufacturer and approved by regulatory authorities. This approved time is indicated by the expiration date printed directly on the labeled product container.


Q: Does Locana impact mental clarity or focus?

Potential central nervous system adverse reactions listed in the official documents include effects such as confusion, dizziness, and drowsiness. These effects may impact a person’s mental clarity or ability to focus.

How should Locana be stored and disposed of?

How to Store and Dispose of Locana?

Specific storage, handling, and disposal requirements for Locana are strictly defined in the official package insert or labeled Patient Information leaflet provided with the medication. Always check the official product labeling before storage or disposal.

Storage

  • Temperature & Protection: Review the manufacturer's directions for the required storage temperature (e.g., room temperature, refrigeration) and any need to protect the medication from light or moisture.
  • Handling: Keep Locana out of the reach of children. Do not use the medication beyond the labeled expiration date.

Disposal

  • Do not flush this medication down a toilet or pour it into a drain unless the product's official labeling explicitly directs this method, as per U.S. Food and Drug Administration (FDA) guidelines.
  • The preferred method for disposal is using a local drug take-back program or a mail-back envelope. If these options are unavailable, mix the medication with an unappealing substance, place it in a sealed container, and discard it in household trash, as recommended by the FDA for most medicines.
  • Follow all federal, state, and local regulations for environmental and controlled-waste disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Locana found in:

A-Z Index: